On January 17, 2023, the State Food and Drug Administration approved the registration and listing of Huisheng-I type ECMO, an extracorporeal lung support auxiliary device developed by Aerospace New Long March Medical Instruments (Beijing) Co., Ltd. (hereinafter referred to as Long March Medical), by means of conditional approval. This product is the second approved domestic ECMO product.
It is reported that the technology of this product is independent and controllable, and has completely independent intellectual property rights. It is transformed from the aerospace technology adopted by the rocket flight control executive system-servo mechanism. It is an important achievement of the application of China's aerospace technology in the high-end medical field, and its performance and indicators reach the international level of similar products.
ECMO is mainly used to provide continuous extracorporeal respiration and blood circulation support for patients with severe cardiopulmonary failure. The core components generally include artificial heart (centrifugal pump host and centrifugal pump head) and artificial lung (membrane lung), which can replace human heart and lung function for a long time, maintain the blood pressure and blood oxygen of patients, and win valuable time for the rescue of critical illness. Therefore, ECMO is regarded as the "gatekeeper" to save lives in ICU.
Long March Medical has successively cooperated with Beijing Union Hospital, Sino-Japanese Friendship Hospital, the General Hospital of the People's Liberation Army of China, Tianjin Taixin Hospital, the Second Hospital of Tianjin Medical University and other top hospitals in China to carry out preclinical large animal experiments and clinical trials for elderly and critically ill patients. The treatment effect is good, fully verifying the reliability, safety and effectiveness of the product.
It is understood that Changzheng Medical is a wholly-owned subsidiary of Beijing Institute of Precision Electromechanical Control Equipment, which is affiliated to the First Academy of China Aerospace Science and Technology Group. It is mainly engaged in technology research and development and industrial incubation of aerospace technology in the high-end medical field, promoting the independent control of China's high-end medical equipment.